Efficacy of Ivabradine Versus Propranolol Premedication During Hypotensive Anesthesia in Endoscopic Sinus Surgery

• Status: Recruiting
• Trial end date: 2020-05-01
• Target enrollment: 0
• Participant gender: All

Summary

50 Patients, aged from 18 to 39 years, ASA physical status I and II, undergoing endoscopic sinus surgery will be enrolled in the study.The patients will be randomly allocated by simple randomization using a computer programme into two groups by closed envelope technique (having 25 patients in each group): GROUP (P): will receive oral propranolol (INDERAL® -propranolol hydrochloride Ph. Eur. 10mg manufactured by AstraZeneca Egypt under license of AstraZeneca UK), 10 mg one tablet at 8:00 pm in the evening before the day of the surgery and one 10 mg tablet one hour before the induction of anesthesia.

GROUP (I): will receive oral ivabradine (Procoralan® 5mg manufactured by Servier laboratories, France), 5 mg one tablet at 8:00 pm in the evening before the day of the surgery and one 5 mg tablet one hour before the induction of anesthesia.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alexandria University
• Treatments: Anesthetics; Antihypertensive Agents; Propranolol

Criteria

Inclusion Criteria:

• ASA physical status I and II, undergoing endoscopic sinus surgery

Exclusion Criteria:

• Patients with cardiovascular disease (hypertension, congestive heart failure, and coronary artery disease).

• Patients on beta-blockers.

• Patients with the base line heart rate<60 beats per minute.

• Patients with diabetes mellitus (DM).

• Cerebrovascular insufficiency.

• Coagulation defects.

• History of renal or hepatic insufficiency.

• Hypersensitivity to the study drugs.

• Patients with history of bronchial asthma